Are allergy drops (liquid SLIT) FDA‑approved in the U.S.?

No. Custom liquid SLIT drops are not FDA‑approved; their use is off‑label. They are typically prepared from FDA‑regulated allergen extracts that are licensed mainly for injection/diagnostic use.

Which SLIT tablets are FDA‑approved and for what ages?

Grastek (Timothy grass), Oralair (5‑grass), Ragwitek (short ragweed), and Odactra (house dust mite) are FDA‑approved. All are labeled for ages 5–65 years.

Do I need my first tablet dose in a clinic and an epinephrine prescription?

Yes. The first dose must be administered under medical supervision with ≥30‑minute observation, and patients are prescribed and trained to use an epinephrine auto‑injector.

Do SLIT tablets work right away?

No. They are disease‑modifying; labels specify they do not provide immediate symptom relief.

Can a tablet treat multiple allergens at once?

No. Each tablet targets a single allergen group. Multi‑allergen desensitization may require shots or off‑label liquid SLIT at a clinician’s discretion.

Introduction

This neutral explainer clarifies the U.S. regulatory status of sublingual immunotherapy (SLIT) “allergy drops” and SLIT tablets as of November 3, 2025, and summarizes who qualifies, what’s on‑label vs. off‑label, and the key safety requirements clinicians follow.

Quick answer

SLIT drops (custom liquid): Not FDA‑approved in the United States; when used they are physician‑directed, off‑label therapies prepared from FDA‑regulated allergen extracts that are licensed primarily for injections/skin testing. Coverage is variable. Clinicians use them for multi‑allergen or non‑tablet targets. Drops are not approved; only tablets are FDA‑approved.
SLIT tablets (on‑label): FDA has approved tablets for three allergen categories—grass pollens, short ragweed, and house dust mite (HDM)—with labeled use in persons 5–65 years. First dose must be given under medical supervision with ≥30‑minute observation, and patients are prescribed epinephrine for emergencies. Tablets do not give immediate symptom relief.

FDA‑approved SLIT tablets at a glance

Brand (allergen)	Labeled ages	When to start	First dose supervised?	Epinephrine required/prescribed?
Grastek (Timothy grass; cross‑reactive northern pasture grasses)	5–65	≥12 weeks before grass season; daily through season	Yes (observe ≥30 min)	Yes (auto‑injector, with training)
Oralair (5‑grass mix)	5–65	~4 months before grass season; daily through season	Yes (observe ≥30 min)	Yes (prescribe/educate)
Ragwitek (short ragweed)	5–65	~12 weeks before ragweed season; daily through season	Yes (observe ≥30 min)	Yes (auto‑injector, with training)
Odactra (house dust mite)	5–65	Any time; year‑round daily	Yes (observe ≥30 min)	Yes (boxed‑warning products require epinephrine)

Labeling defines ages, timing, and safety steps; Odactra’s indication expanded to ages 5–65 in February 2025.

Safety and eligibility essentials (tablets)

First dose location: Give the initial tablet in a medical facility with staff and supplies to manage anaphylaxis; observe for at least 30 minutes. Subsequent dosing is at home.
Epinephrine: Prescribe and train each patient (or caregiver) to use an epinephrine auto‑injector; provide an action plan.
Not for immediate relief: SLIT tablets are disease‑modifying and do not treat acute symptoms.
Common label cautions: Avoid initiation in severe/unstable asthma; prior severe SLIT reactions; or eosinophilic esophagitis. Hold dosing with significant oral inflammation/procedures until healed.

Off‑label SLIT drops in the U.S.: how they fit

What “off‑label” means here: U.S. clinicians may prescribe liquid SLIT using FDA‑licensed allergen extracts for sublingual use, even though no liquid SLIT products are FDA‑approved. This is legal off‑label practice, typically cash‑pay, and protocols vary by physician.
Why used: tablets are single‑allergen; liquid SLIT can be personalized to multiple inhalant allergens (e.g., cat/dog, molds, certain tree/weed pollens) when no FDA‑approved tablet exists. Professional society education emphasizes that only tablets are FDA‑approved in the U.S.

Who qualifies (ages and indications)

Labeled tablet ages: 5–65 years for grass (Grastek, Oralair), ragweed (Ragwitek), and HDM (Odactra). Diagnosis should be confirmed by positive specific IgE (blood) or skin testing to the target allergen.

Practical notes for clinicians and patients

Single vs. multi‑allergen strategy: Tablets treat one allergen each; consider liquid SLIT (off‑label) or shots when multi‑allergen desensitization is needed.
Tablets require planning: Start pre‑season for pollens (grass, ragweed) and continue through the season; start any time for Odactra. Reinforce adherence and emergency action training.

Source highlights (labels and regulators)

Injectable extracts and SLIT tablets are licensed categories.
Grastek U.S. Prescribing Information (ages 5–65; first dose in clinic; epinephrine; ≥12‑week pre‑season start).
Oralair label/HCP resources (ages 5–65; first dose observed; seasonal pre‑start; epinephrine).
Ragwitek Prescribing Information (ages 5–65; first dose in clinic; daily dosing through season).
Odactra update/product page (indication expanded to 5–65 on Feb 27–28, 2025; boxed warning; epinephrine).
Only tablets are FDA‑approved SLIT in U.S.; drops are not FDA‑approved.

Are allergy drops FDA‑approved? Which tablets are FDA‑approved (U.S., 2025)?